1. PCSK9-Inhibitor treatment of cardiovascular high risk patients in clinical practice – New data regarding safety and effectivity. (August 2018) Authors: Hollstein, T.; Grenkowitz, T.; Scharnagl, H.; März, W.; Steinhagen-Thiessen, E.; Kassner, U. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies (Pcsk9-I) Treatment Of Cardiovascular High Risk Patients In Clinical Practice. (August 2019) Authors: Kassner, U.; Hollstein, T.; Schumann, F.; Grenkowitz, T.; Scharnagl, H.; März, W.; Steinhagen-Thiessen, E. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗